



Metrics from C-Path Data Activities

November 13, 2018

Mr. Rick Liwski
Chief Technology Officer
Critical Path Institute



Data Sharing and Aggregation - Metrics

C-Path's Online Data Repository (CODR)

Database/Project Name	Therapeutic Area	TOTAL		IN CODR		Accessibility
		# Studies	# Patients	# Studies	# Subjects	
CPAD	Alzheimer's disease	37	13904	28	6955	External
Catalysis Health Foundation Database	Tuberculosis	1	219	1	219	External
CPTR-CDC	Tuberculosis	5	2715	3	1850	External
Duchenne Regulatory Science Consortium	Duchenne Muscular Dystrophy	12	4562	4	3991	External
Friedreich's Ataxia Integrated Clinical Database	Friedreich's Ataxia	5	1414	4	340	Not Available Yet
MS Placebo Data	Multiple Sclerosis	18	15626	9	2464	External
Critical Path for Parkinson's	Parkinson's disease	13	8940	6	5354	External
Polycystic Kidney Disease	Polycystic Kidney Disease	5	2941	3	2498	External
Patient Reported Outcome Consortium		1	60	0	0	Internal Use Only
PSTC Normal healthy Volunteer Study	Kidney Disease	1	172	0	0	Internal Use Only
T1D	Type 1 Diabetes	6	206	0	0	Not Available Yet
CPTR-Modelling	Tuberculosis	5	856	0	0	Internal Use Only
TB-PACTS 2.0	Tuberculosis	18	13159	17	12234	External
TOTALS		127	64774	75	35905	

As of October 2018; external means external to C-Path (e.g., consortium only)


Relational Sequencing TB Platform (ReSeqTB) Data Inventory

The Relational Sequencing TB Platform (ReSeqTB) was launched in 2015 as a collaborative, cross-sector endeavor in response to the urgent need for a well-curated resource to identify, categorize, and interpret pathogen genomic mutations associated with drug resistance. Contributed isolates are processed through a unified variant reporting bioinformatics pipeline, then curated, standardized and integrated into a single, aggregated database.

Database Name	Therapeutic Area	# Isolates Total	# Isolates in ReSeqTB	# Isolates in Process	Accessibility
ReSeqTB	Tuberculosis	12,707	9,207	3500	External

Clinical Data Growth (June 2014 – June 2018)


Clinical data contributed to C-Path



Data Platform Access by Sector

Sector	Active	Pending	Total
Academia	328	3	331
Government	87		87
Non-profit	66		66
Pharmaceutical	162	1	163
Other	81	1	82
(UNKNOWN)	28		28
Total	752	5	757

Data Platform Access by Geography



Clinical Trial Simulation Tool

C-Path and the Critical Path for Alzheimer's Disease (CPAD) Consortium have developed a clinical trial simulation tool to help optimize clinical trial design for mild and moderate AD, using ADAS-cog as the primary cognitive endpoint. The tool is based on a drug-disease-trial model that describes disease progression, drug effects, dropout rates, placebo effect, and relevant sources of variability using data collected through the CPAD (formerly CAMD) consortium.

C-Path makes this tool freely available to qualified researchers through the CODR platform access request process. To date, the AD Clinical Trial Simulation Tool has been requested by 104 applicants, and 84 of those requests have been approved.